Navigating Skyrizi Prior Authorization for Urology Patients

Managing prior authorizations for patients on systemic therapies like Skyrizi, especially when they also require urological care, introduces unique complexities for revenue cycle teams. Klivira streamlines the Skyrizi prior authorization for urology practices by providing a comprehensive view of patient medication profiles.

While Skyrizi (risankizumab) is an IL-23 inhibitor primarily indicated for conditions such as plaque psoriasis, psoriatic arthritis, and Crohn's disease, urology practices may encounter its prior authorization in the context of co-managing patients with multiple chronic conditions. These patients often require integrated care across specialties, necessitating a robust prior authorization strategy that accounts for all prescribed medications.

The Role of Skyrizi (Risankizumab) in Patient Care

Skyrizi is a targeted biologic therapy that inhibits interleukin-23 (IL-23), a cytokine involved in inflammatory and autoimmune responses. Its established indications are outside the primary scope of urology, focusing on inflammatory conditions managed by specialists in dermatology and gastroenterology. Understanding its mechanism and indications is crucial when a urology practice supports a patient on this therapy.

Intersection of Systemic Therapies and Urological Care

Patients with chronic inflammatory conditions requiring drugs like Skyrizi may also present with urological issues such as BPH, OAB, stone disease, or prostate cancer. In these scenarios, urology teams must consider the patient's full medication regimen, including systemic biologics, for potential drug interactions, surgical clearance, or overall health status impacting urological treatment plans. Effective prior authorization processes must account for this holistic patient view.

Key Considerations for Urology Practices Managing Patients on Skyrizi

Co-management of patients with inflammatory conditions and urological needs.
Assessing potential drug interactions between Skyrizi and urological medications.
Evaluating the impact of systemic therapy on surgical clearance for urological procedures.
Maintaining a comprehensive patient medication profile for coordinated care.
Facilitating communication and documentation with prescribing dermatologists or gastroenterologists.

Prior Authorization Documentation for Complex Patients

While urologists typically follow AUA Clinical Practice Guidelines and NCCN for urologic oncology, prior authorization for systemic therapies like Skyrizi will adhere to guidelines specific to its indications (e.g., ACR for psoriatic arthritis, ACG for Crohn's disease). Urology practices encountering such PAs should ensure that patient records clearly articulate the medical necessity for *urological* treatments in the context of existing systemic therapies, and coordinate with the initiating specialist for Skyrizi-specific documentation.

Klivira's Platform for Comprehensive Prior Authorization Management

Klivira's platform is designed to manage the complexities of prior authorization across specialties, including those involving systemic therapies and urological care. By integrating with EMRs and connecting to payer portals via channels like X12 278 and ePA, Klivira helps ensure all necessary documentation is compiled and submitted. Our system supports the nuanced requirements for both urology-specific PAs (e.g., prostate cancer therapeutics, BPH treatments) and broader systemic therapies, facilitating coordinated care for complex patients.

Frequently asked questions

Why would a urology practice encounter Skyrizi prior authorization?

A urology practice would typically encounter Skyrizi prior authorization when co-managing a patient who is already prescribed Skyrizi by another specialist (e.g., a dermatologist or gastroenterologist) for conditions like psoriasis or Crohn's disease, but also requires urological care. The urology team may need to be aware of the patient's full medication profile for treatment planning and care coordination.

What are Skyrizi's primary indications?

Skyrizi (risankizumab) is an IL-23 inhibitor indicated for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. These are chronic inflammatory conditions typically managed by specialists in dermatology, rheumatology, and gastroenterology, respectively.

How does Klivira support PA for patients on multiple specialty drugs?

Klivira's platform provides a centralized system for managing prior authorizations across multiple specialties and drug classes. It integrates with EMRs to pull relevant patient data, applies payer-specific policy logic, and automates submission via various channels, helping practices manage all PAs for complex patients efficiently, regardless of the prescribing specialty.

Are there specific urological conditions that Skyrizi treats?

No, Skyrizi is not indicated for the treatment of any specific urological conditions. Its approved indications are for inflammatory diseases such as plaque psoriasis, psoriatic arthritis, and Crohn's disease. Any involvement of a urology practice would be in the context of managing co-morbid urological issues in a patient already on Skyrizi for one of its approved indications.

What guidelines apply for Skyrizi prior authorization?

Prior authorization for Skyrizi typically follows clinical guidelines relevant to its approved indications, such as those from the American College of Rheumatology (ACR) for psoriatic arthritis or the American College of Gastroenterology (ACG) for Crohn's disease. Payers will assess medical necessity based on these specialty-specific criteria.